Welcome to our dedicated page for Renovorx SEC filings (Ticker: RNXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RenovoRx, Inc. (RNXT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, registration statements, and other documents filed with the U.S. Securities and Exchange Commission. RenovoRx is a life sciences company developing targeted oncology therapies and commercializing RenovoCath®, an FDA‑cleared local drug‑delivery device enabled by its patented Trans‑Arterial Micro‑Perfusion (TAMP™) therapy platform.
Through its SEC filings, RenovoRx reports financial results, commercialization progress for RenovoCath, and updates on its clinical development programs. For example, Form 8‑K filings have referenced quarterly financial press releases that discuss revenue from RenovoCath sales, expansion of cancer center customers, and advancement of the Phase III TIGeR‑PaC trial evaluating intra‑arterial gemcitabine (IAG) delivered via RenovoCath in locally advanced pancreatic cancer.
Filings also describe capital markets activity. In a Form 8‑K dated November 14, 2025, RenovoRx reported entering into a Capital on Demand™ Sales Agreement with a sales agent, allowing the company to issue and sell shares of common stock in at‑the‑market offerings or negotiated transactions under an effective shelf registration statement on Form S‑3. Related exhibits include the sales agreement and a legal opinion on the validity of the shares.
On Stock Titan, users can review these filings alongside AI‑generated highlights that help explain key sections, such as risk factor updates, financing terms, and business strategy disclosures. Investors can also monitor current reports that incorporate press releases detailing clinical milestones, registry studies, Scientific Advisory Board changes, and commercialization strategy for RenovoCath and the TAMP platform.
In addition, this page is a starting point for tracking RenovoRx’s ongoing reporting obligations, including future quarterly and annual reports, as well as any additional Forms 8‑K that may discuss clinical trial developments, capital raises, or changes in governance.
Renovorx, Inc. reports amended beneficial ownership disclosure. Orin Hirschman and affiliated entities jointly report ownership of 4,430,439 shares of Common Stock, representing 9.8%. The filing states this amount excludes 2,082,623 common shares issuable upon exercise of warrants that are not currently exercisable due to a beneficial ownership limitation. The amendment is jointly filed by AIGH Capital Management LLC, AIGH Investment Partners LLC, and Mr. Hirschman.
RenovoRx, Inc. files a registration statement to permit resale of up to 8,438,790 shares of common stock, 2,200,000 pre-funded-warrant shares, and 5,319,392 milestone-warrant shares by selling stockholders. These securities were issued in a March 2026 private placement and are being registered for resale by the holders.
The company will not receive proceeds from resales, although it may receive up to $9.3 million if all Milestone Warrants are exercised for cash. The common stock trades on Nasdaq under the symbol RNXT; the last reported sale price was $1.02 per share on April 15, 2026.
RenovoRx, Inc. Chief Executive Officer Shaun Bagai received a grant of stock options covering 946,107 shares of common stock at an exercise price of $0.98 per share. The grant was approved by the Compensation Committee.
The options vest over four years at 1/48 per month starting January 1, 2026, becoming fully vested on January 1, 2030, and expiring on April 3, 2036. They are only exercisable when there is an effective registration statement covering the underlying shares.
VOLL MARK reported acquisition or exercise transactions in this Form 4 filing.
RenovoRx, Inc. reported that Chief Financial Officer Mark Voll received an award of 80,000 shares of Common Stock on April 3, 2026, reflecting stock-based compensation rather than an open-market purchase. The award stems from grants of restricted stock units for his service as CFO.
The footnote explains this consists of 8,777 RSUs for February 2026, 12,270 RSUs for March 2026, and 58,953 RSUs for future service, with the February and March RSUs fully vested upon grant and the remainder vesting monthly. After the transaction, he holds 117,380 shares directly and 97,200 shares indirectly through the Voll Family Trust.
RenovoRx, Inc. reported that Chief Clinical Officer Leesa Gentry received a grant of stock options to purchase up to 128,550 shares of common stock at an exercise price of $0.98 per share. The options vest over four years at a rate of 1/48 per month, with vesting starting on January 1, 2026, and becoming fully vested on January 1, 2030.
The options are exercisable only when there is an effective registration statement covering the underlying shares and will expire on April 3, 2036. Following this grant, Gentry holds 128,550 stock options directly.
RenovoRx, Inc. granted its Chief Medical Officer, Ramtin Agah, stock options to purchase 621,727 shares of common stock. The options have an exercise price of $0.98 per share and were approved by the Compensation Committee.
The grant consists of 319,073 shares underlying incentive stock options and 302,654 shares underlying non-qualified stock options. Vesting occurs over four years at 1/48 per month, beginning January 1, 2026, becoming fully vested on January 1, 2030. The options are exercisable only when there is an effective registration statement covering the underlying shares and will expire on April 3, 2036. Following this award, the reporting person holds 621,727 derivative securities.
RenovoRx reported full-year 2025 results and a business update. Revenue rose to $1.1 million from $43,000 in 2024, reflecting the first full year of RenovoCath commercialization across U.S. cancer centers. Net loss widened to $11.2 million from $8.8 million as the company invested in its Phase III TIGeR-PaC trial and commercial buildout.
Cash and cash equivalents were $7.0 million at December 31, 2025, and an oversubscribed March 2026 private placement added $10 million in gross proceeds, leaving about $13 million on hand. As of March 24, 2026, the TIGeR-PaC trial had randomized 104 patients with 72 events toward a 114-patient, 86-event target, and 12 cancer centers were actively using RenovoCath with additional centers in the pipeline.
RenovoRx, Inc. reports its annual results and business progress for the year ended December 31, 2025. The company generated $1.1 million in revenue from U.S. sales of its FDA‑cleared RenovoCath device, used for targeted intra‑arterial drug delivery in cancer care.
RenovoCath adoption is expanding, with 12 U.S. cancer centers using the device and a total of 33 centers requesting access, supported by more than 700 clinical procedures to date. RenovoRx is also advancing its TAMP therapy platform and IAG drug–device combination in the Phase III TIGeR‑PaC trial for locally advanced pancreatic cancer, where an initial interim analysis showed a 6‑month median overall survival benefit and over 65% fewer adverse events versus standard intravenous chemotherapy, leading the independent Data Monitoring Committee to recommend continuation.
VOLL MARK reported acquisition or exercise transactions in this Form 4 filing.
RenovoRx, Inc. chief financial officer Mark Voll reported an equity grant of 12,380 shares of common stock. These shares were granted as restricted stock units for his service as a consultant of the company for January 2026 and carry a stated price of $0.00 per share.
Following this grant, Voll directly holds 37,380 shares of common stock and has an additional 97,200 shares reported as indirectly held through the Voll Family Trust DTD 6/23/2010, with Mark Voll as trustee. This filing reflects compensation rather than an open-market stock purchase.
RenovoRx, Inc. filed an amended initial ownership report showing that Chief Financial Officer Mark Voll beneficially owns 25,000 shares of the company’s common stock. These shares are held directly and, according to a footnote, were purchased in open‑market transactions before he became CFO.